Affiliation:
1. Clinical Trials
Unit, Special Unit for Biomedical Research and Education & Department of Clinical Pharmacology School of Medicine,
Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
2. DRK Kliniken Berlin Köpenick, Neurology Department, S.-Allende-Str. 2-8, 12555, Berlin, Germany
Abstract
Background:
Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS) are widely
used given their proven efficacy in the relapsing form of the disease, while recently, Siponimod and
Ocrelizumab have been approved for the progressive forms of the disease. Currently, 22 diseasemodifying
drugs are approved by the FDA, while in 2012, only nine were present in the market. From
March 2019 until August 2020, six new drugs were approved. This rapid development of new DMTs
highlighted the need to update our knowledge about their short and long-term safety.
Objective:
A literature search was conducted using PUBMED and COCHRANE databases. Key journals
and abstracts from major annual meetings of Neurology, references of relevant reviews, and relative
articles were also manually searched. We prioritized systematic reviews, large randomized controlled
trials (RCTs), prospective cohort studies, and other observational studies. Special attention was
paid to guidelines and papers focusing on the safety and monitoring of DMTs.
Methods:
A literature search was conducted in PUBMED and COCHRANE databases. Also, we manually searched key journals and abstracts from major annual meetings of Neurology, references of relevant reviews, and relative articles. We prioritized systematic reviews, large randomized controlled trials (RCTs), prospective cohort studies, and other observational studies. Special attention was paid to guidelines and papers focusing on the safety and monitoring of DMTs. Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide, Cladribine), injectables (Interferons, Glatiramer acetate, Ofatumumab), and infusion therapies (Natalizumab, Ocrelizumab, Alemtuzumab) are presented.
Conclusion:
Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide,
Cladribine), injectables (Interferons, Glatiramer acetate, Ofatumumab), and infusion therapies
(Natalizumab, Ocrelizumab, Alemtuzumab) are presented.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics